Lifecore Biomedical, Inc. (NASDAQ:LFCR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Lifecore Biomedical, Inc. (NASDAQ:LFCR) has received a consensus recommendation of "Moderate Buy" from four brokerages, with an average 1-year price target of $8.00.
• Various institutional investors have significantly increased their stakes in Lifecore, with GAMMA Investing LLC raising its position by 1,839.7% in the first quarter.
• The company's recent earnings report indicated a loss of ($0.10) EPS, missing expectations, while announcing a revenue of $36.44 million for the quarter.

Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the four brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.00.

LFCR has been the topic of a number of research analyst reports. Weiss Ratings reiterated a "sell (d)" rating on shares of Lifecore Biomedical in a research note on Saturday, September 27th. KeyCorp assumed coverage on shares of Lifecore Biomedical in a report on Wednesday, September 3rd. They set a "sector weight" rating on the stock. Finally, Wall Street Zen raised shares of Lifecore Biomedical from a "sell" rating to a "hold" rating in a report on Saturday, August 16th.

Institutional Investors Weigh In On Lifecore Biomedical

Several institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Lifecore Biomedical by 1,839.7% in the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock worth $25,000 after purchasing an additional 3,385 shares during the period. Summit Securities Group LLC bought a new stake in shares of Lifecore Biomedical in the first quarter worth approximately $26,000. Hurley Capital LLC bought a new stake in shares of Lifecore Biomedical in the first quarter worth approximately $35,000. State of Wyoming purchased a new position in Lifecore Biomedical during the second quarter valued at $69,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Lifecore Biomedical in the second quarter worth about $88,000. Hedge funds and other institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Stock Down 1.1%

Shares of NASDAQ:LFCR traded down $0.08 during midday trading on Friday, hitting $6.98. 202,873 shares of the company's stock were exchanged, compared to its average volume of 211,277. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.84 and a quick ratio of 1.77. The stock has a 50 day moving average price of $7.44 and a 200-day moving average price of $7.10. The company has a market cap of $261.51 million, a PE ratio of -5.33 and a beta of 0.62. Lifecore Biomedical has a 12 month low of $4.33 and a 12 month high of $8.85.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%.The business had revenue of $36.44 million for the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS. On average, sell-side analysts anticipate that Lifecore Biomedical will post -0.91 EPS for the current fiscal year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.